<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36681358</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2139</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain, behavior, and immunity</Title><ISOAbbreviation>Brain Behav Immun</ISOAbbreviation></Journal><ArticleTitle>Profiling TREM2 expression in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>117</StartPage><EndPage>126</EndPage><MedlinePgn>117-126</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbi.2023.01.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0889-1591(23)00013-2</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">There is growing evidence of the contribution of neuroinflammation, and in particular microglia, in the pathogenesis of amyotrophic lateral sclerosis (ALS). TREM2 gene plays a crucial role in shaping microglia in neurodegenerative conditions. To deepen the understanding of TREM2 in ALS and investigate the performance of TREM2 as a biomarker, we profiled TREM2 expression levels in spinal cord, cerebrospinal fluid and blood of patients with sporadic ALS. We also wanted to investigate whether the combined measurement of sTREM2 in fluids could improve the diagnostic yield of total and phosphorylated TDP-43 levels.</AbstractText><AbstractText Label="METHODS">We performed a case-control study to profile overall and transcript-specific TREM2 mRNA levels by RT-qPCR and protein expression levels by Western-blot in postmortem specimens of spinal cord from ALS patients and controls. In parallel, we measured soluble TREM2 (sTREM2) protein levels and full length and phosphorylated TDP-43 (tTDP-43 and pTDP-43) by ELISA in CSF and serum from ALS patients vs healthy controls. Patients were prospectively recruited from an ALS unit of a tertiary hospital and fulfilled El Escorial revised criteria. After bivariate analysis, a logistic regression model was developed to identify adjusted estimates of the association of sTREM2 levels in CSF and serum with ALS status.</AbstractText><AbstractText Label="RESULTS">Overall and transcript-specific TREM2 mRNA were upregulated in the spinal cord of ALS patients (n&#xa0;=&#xa0;21) compared to controls (n&#xa0;=&#xa0;19). Similar changes were observed in TREM2 protein levels (p&#xa0;&lt;&#xa0;0.01) in spinal cord of ALS patients vs healthy controls. We also detected significantly higher sTREM2 levels in CSF (p-value&#xa0;&lt;&#xa0;0.01) of ALS patients (n&#xa0;=&#xa0;46) vs controls (n&#xa0;=&#xa0;46) and serum (p-value&#xa0;&lt;&#xa0;0.001) of ALS patients (n&#xa0;=&#xa0;100) vs controls (n&#xa0;=&#xa0;100). In a logistic regression model, both CSF and serum sTREM2 remained independently associated with ALS status with OR&#xa0;=&#xa0;3.41 (CI 95&#xa0;%=1.34-8.66) (p-value&#xa0;&lt;&#xa0;0.05) and OR&#xa0;=&#xa0;3.38 (CI 95&#xa0;%: 1.86-6.16) (p-value&#xa0;&lt;&#xa0;0.001), respectively. We also observed that pTDP-43 levels in CSF is an independent predictor of ALS (p-value&#xa0;&lt;&#xa0;0.05).</AbstractText><AbstractText Label="CONCLUSIONS">Our results support the role of TREM2 in ALS pathophysiology and demonstrates that the three TREM2 transcripts are deregulated in ALS in postmortem human specimens of spinal cord. We hypothesise about the possible influence of systemic-peripheral inflammation in the disease. Finally, we conclude that pTDP-43 levels in CSF could be a biomarker of ALS, and sTREM2 measurement in CSF and blood emerge as potential non-invasive biomarker in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeric&#xf3;</LastName><ForeName>Ivonne</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Navarra-IdisNA (Navarra Institute of Health Research), Pamplona, Spain; Neuromuscular and Neuron Motor Neuron Diseases Laboratory, IdisNA (Navarra Institute of Health Research), Pamplona, Spain. Electronic address: ijericop@cfnavarra.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicu&#xf1;a-Urriza</LastName><ForeName>Janire</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroepigenetics Laboratory-Navarrabiomed, IdisNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco-Luquin</LastName><ForeName>Idoia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuroepigenetics Laboratory-Navarrabiomed, IdisNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macias</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroepigenetics Laboratory-Navarrabiomed, IdisNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Merino</LastName><ForeName>Leyre</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Navarra-IdisNA (Navarra Institute of Health Research), Pamplona, Spain; Neuromuscular and Neuron Motor Neuron Diseases Laboratory, IdisNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rold&#xe1;n</LastName><ForeName>Miren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroepigenetics Laboratory-Navarrabiomed, IdisNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Garcia</LastName><ForeName>Ricard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Motor Neuron Diseases Clinic, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain; Neuromuscular Diseases Laboratory, Institut de Recerca Hospital de St. Pau (IIB Sant Pau), Barcelona and Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagola-Lorz</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Navarra-IdisNA (Navarra Institute of Health Research), Pamplona, Spain; Neuromuscular and Neuron Motor Neuron Diseases Laboratory, IdisNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbayo</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Motor Neuron Diseases Clinic, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Luna</LastName><ForeName>Noemi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Laboratory, Institut de Recerca Hospital de St. Pau (IIB Sant Pau), Barcelona and Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelaya</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Hospital of Navarra- IdiSNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendioroz</LastName><ForeName>Maite</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Navarra-IdisNA (Navarra Institute of Health Research), Pamplona, Spain; Neuroepigenetics Laboratory-Navarrabiomed, IdisNA (Navarra Institute of Health Research), Pamplona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Behav Immun</MedlineTA><NlmUniqueID>8800478</NlmUniqueID><ISSNLinking>0889-1591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Peripheral inflammation</Keyword><Keyword MajorTopicYN="N">Serum and CSF</Keyword><Keyword MajorTopicYN="N">Soluble TREM2</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">TREM2 isoforms</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36681358</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2023.01.013</ArticleId><ArticleId IdType="pii">S0889-1591(23)00013-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>